Honigman Advises Helius Medical Technologies on $9.1 Million Public Offering

Helius Medical Technologies, Inc. (NASDAQ: HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, closed its public offering of 2,768,600 shares of Class A common stock (or common stock equivalents), and warrants to purchase up to 2,768,600 shares of common stock, at a combined public offering price of $3.27 per share and accompanying warrants. The offering closed on June 6, 2025.

Honigman represented Helius in the offering, led by Corporate Partners Phillip D. Torrence, N. Danny Shulman and Jeffrey H. Kuras, with support from Associates Garrett D. Packer and Sarah E. Meinel.